Tiếp theo

Tự chạy

FDA Approvals in NSCLC and Soft Tissue Sarcoma, Priority Review in Bladder Cancer, and More

1 Lượt xem • 07/18/23
Đăng lại
Nhúng
administrator
administrator
Người đăng ký
0

Justin Gallagher reports two FDA approvals for immunotherapy in lung cancer, an approval in soft tissue sarcoma, a priority review designation in bladder cancer, an updated indication for a drug in prostate cancer, encouraging phase III results in bladder cancer, noninferiority findings in multiple myeloma, and a European approval in pancreatic cancer.

Cho xem nhiều hơn
0 Bình luận sort Sắp xếp theo
Bình luận trên Facebook

Tiếp theo

Tự chạy